Trial of Covaxin on 2-18 years age group likely to begin in 10-12 days, a government official has said.
NEW DELHI: Trial of Bharat Biotech's Covaxin in the 2-18 years age group is likely to begin in the next 10-12 days. This was stated today by VK Paul, member of NITI Aayog (Health)while speaking to the media today.
Drugs Controller General of India (DCGI) had last week approved Covaxin for Phase II/III clinical trials in that age group.
Speaking on use of DRDO's Covid drug 2DG, Paul said "We will examine the drug in Covid-19 National Task Force for adding it to the treatment protocol." The drug already has DCGI approval for emergency use on Covid patients.
Speaking at the same event, health ministry official Luv Agarwal said that 1.8% of total population of India has been affected by the disease so far. That means nearly 98% people are still vulnerable to the infection.
Commenting on the current trends of infections and recoveries, Agarwal informed that 199 districts have shown continued decline in cases and positivity since last 3 weeks.
8 states now have more than 1 lakh active cases, 10 states have 50,000-1,00,00 and 18 have less than 50,000.
The overall positivity rate in the country now stands at 14.10%.
Recovery rate too has improved from 81.7% on My 3 to 85.6% now, with number of recoveries crossing 4 lakh for the first time yesterday, Agarwal said.